Skip to main content
. 2015 Jul 6;112(29):E3855–E3863. doi: 10.1073/pnas.1510733112

Fig. S1.

Fig. S1.

Gefitinib paradoxically activates ERK1/2 in EGFR-mutated NSCLC cells after 6–24 h of incubation. Western blot analysis. Exponentially growing HCC827 cells were treated with various concentrations of gefitinib and collected after 1 h (A), 6 h (B), 12 h (C), and 24 h (D) of treatment.